EULAR: Obexelimab Can Lower Risk for Disease Flare in Active IgG4-Related Disease

MONDAY, June 8, 2026-- For patients with active immunoglobulin (Ig)G4-related disease, obexelimab, a bifunctional monoclonal antibody that inhibits B-cell activity, yields a significantly lower risk for disease flare, according to a study...